Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) Director Deborah Andrews bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The shares were acquired at an average price of $0.80 per share, with a total value of $20,000.00. Following the acquisition, the director owned 40,578 shares of the company’s stock, valued at $32,462.40. This represents a 160.48% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Lineage Cell Therapeutics Price Performance
NYSEAMERICAN:LCTX traded up $0.02 during trading hours on Tuesday, hitting $0.82. The company had a trading volume of 6,784,316 shares, compared to its average volume of 1,368,579. The company has a market capitalization of $206.32 million, a PE ratio of -9.06 and a beta of 1.68. The stock has a 50-day moving average price of $0.99 and a 200 day moving average price of $1.29. Lineage Cell Therapeutics, Inc. has a 52 week low of $0.77 and a 52 week high of $1.99.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). Lineage Cell Therapeutics had a net margin of 16.18% and a return on equity of 3.37%. The business had revenue of $1.43 million during the quarter, compared to analyst estimates of $2.32 million. Analysts anticipate that Lineage Cell Therapeutics, Inc. will post -0.07 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Separately, Raymond James Financial reiterated a “market perform” rating on shares of Lineage Cell Therapeutics in a research report on Friday. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.25.
Get Our Latest Stock Report on LCTX
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.
Featured Stories
- Five stocks we like better than Lineage Cell Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
